Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
Biogen paid Ionis a US $ 60 million one-time upfront payment
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Subscribe To Our Newsletter & Stay Updated
